Behind the Scenes of Amgen's Latest Options Trends
Behind the Scenes of Amgen's Latest Options Trends
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMGN, it often means somebody knows something is about to happen.Investors with a lot of money to spend have taken a bullish stance on Amgen (NASDAQ:AMGN).
有大量资金的投资者对Amgen（纳斯达克：安进）持看好态度。
And retail traders should know.
零售交易者应该知道。
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
我们在这里追踪的公开期权历史记录上看到交易时发现了这一点。
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMGN, it often means somebody knows something is about to happen.
不管这些投资者是机构还是富有的个人，我们不得而知。但当AMGN发生如此重大的事件时，通常意味着有人知道即将发生的事情。
So how do we know what these investors just did?
那么我们如何知道这些投资者刚刚做了什么呢？
Today, Benzinga's options scanner spotted 8 uncommon options trades for Amgen.
今天，Benzinga的期权扫描器发现了Amgen的8笔异常期权交易。
This isn't normal.
这不正常。
The overall sentiment of these big-money traders is split between 50% bullish and 25%, bearish.
这些大资金交易者的整体情绪在50%看好和25%看淡之间分裂。
Out of all of the special options we uncovered, 6 are puts, for a total amount of $201,232, and 2 are calls, for a total amount of $119,247.
在我们发现的所有特殊期权中，有6个看跌期权，总额为201,232美元，有2个看涨期权，总额为119,247美元。
Predicted Price Range
预测价格区间
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $280.0 to $370.0 for Amgen over the recent three months.
根据交易活动，看起来重要投资者的目标是安进股票在最近三个月的价格区间，从280.0美元到370.0美元。
Volume & Open Interest Trends
成交量和未平仓量趋势
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Amgen's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Amgen's substantial trades, within a strike price spectrum from $280.0 to $370.0 over the preceding 30 days.
评估成交量和未平仓合约是期权交易的战略步骤。这些指标揭示了在指定行权价格下，安进期权的流动性和投资者兴趣。即将公布的数据将可视化地呈现了过去30天内，从280.0美元到370.0美元的行权价格范围内，看跌期权和看涨期权的成交量和未平仓合约的波动，这与安进股票的大宗交易有关。
Amgen 30-Day Option Volume & Interest Snapshot
安进30天期权成交量和持仓量快照
Biggest Options Spotted:
最大的期权交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | CALL | SWEEP | BEARISH | 12/20/24 | $10.55 | $10.1 | $10.2 | $370.00 | $78.2K | 649 | 80 |
| AMGN | PUT | SWEEP | BULLISH | 10/18/24 | $7.1 | $5.55 | $6.3 | $335.00 | $48.5K | 628 | 46 |
| AMGN | CALL | TRADE | BEARISH | 10/18/24 | $59.45 | $58.55 | $58.55 | $280.00 | $40.9K | 89 | 7 |
| AMGN | PUT | SWEEP | NEUTRAL | 01/17/25 | $14.3 | $14.2 | $14.2 | $315.00 | $39.7K | 607 | 53 |
| AMGN | PUT | SWEEP | BULLISH | 10/04/24 | $3.45 | $3.25 | $3.25 | $332.50 | $32.5K | 4 | 100 |
| 标的 | 看跌/看涨 | 交易类型 | 情绪 | 到期日 | 卖盘 | 买盘 | 价格 | 执行价格 | 总交易价格 | 未平仓合约数量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | 看涨 | SWEEP | 看淡 | 12/20/24 | $10.55 | $10.1 | $10.2 | $370.00 | $78.2千美元 | 649 | 80 |
| AMGN | 看跌 | SWEEP | 看好 | 10/18/24 | $7.1 | $5.55 | $6.3 | 335.00美元 | $48.5K | 628 | 46 |
| AMGN | 看涨 | 交易 | 看淡 | 10/18/24 | $59.45 | $58.55 | $58.55 | $280.00 | $40.9千 | 89 | 7 |
| AMGN | 看跌 | SWEEP | 中立 | 01/17/25 | $14.3 | 14.2 | 14.2 | $315.00 | $39.7K | 607 | 53 |
| AMGN | 看跌 | SWEEP | 看好 | 10/04/24 | $3.45 | $3.25 | $3.25 | $332.50 | $32.5K | 4 | 100 |
About Amgen
关于安进
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
安进是生物技术制药领域的领导者。旗舰药物包括增加红细胞计数的艾普毕与阿拉尼许、增强免疫系统的奈帕姆和奈乌细胞移植因子、以及针对炎症性疾病的恩布瑞尔和欧特兹拉。安进在2006年推出了首个癌症治疗药物Vectibix，并推出了增强骨密度的药物Prolia/Xgeva（于2010年获批）和Evenity（于2019年获批）。对Onyx的收购增强了该公司在治疗肿瘤领域的药物组合，其中包括Kyprolis。最近推出的药物包括Repatha（降低胆固醇）、Aimovig（缓解偏头痛）、Lumakras（治疗肺癌）以及Tezspire（治疗哮喘）。2023年Horizon收购带来了几种罕见疾病药物，其中包括治疗甲状腺眼病的Tepezza。安进还拥有不断增长的生物类似物组合。
In light of the recent options history for Amgen, it's now appropriate to focus on the company itself. We aim to explore its current performance.
考虑到安进近期期权的历史，现在适当关注该公司本身。我们旨在探讨其当前业绩。
Present Market Standing of Amgen
安进的当前市场状况
- Currently trading with a volume of 759,929, the AMGN's price is up by 1.08%, now at $336.52.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 40 days.
- 目前成交量为759,929股，AMGN股票价格上涨1.08%，目前为336.52美元。
- RSI读数表明该股目前可能接近超买水平。
- 预计财报发布还有40天。
Unusual Options Activity Detected: Smart Money on the Move
检测到期权异动：智慧资金在行动。
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.
Benzinga Edge的期权异动模块可以提前发现潜在的市场热点。了解大笔的资金在您喜欢的股票上的仓位变动。点击这里获取访问权限。
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
期权与仅交易股票相比是一种更具风险的资产，但它们具有更高的利润潜力。认真的期权交易者通过每日学习，进出交易，跟随多个指标并密切关注市场来管理这种风险。
